A citation-based method for searching scientific literature

Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
Times Cited: 212



Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
Times Cited: 502




List of shared articles



Times cited

Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Jaime Blais, Qiang Li, Meg J Jardine,[...]. Am J Kidney Dis 2021
5

Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Husam M Salah, Subhi J Al'Aref, Muhammad Shahzeb Khan, Malek Al-Hawwas, Srikanth Vallurupalli, Jawahar L Mehta, J Paul Mounsey, Stephen J Greene, Darren K McGuire, Renato D Lopes,[...]. Am Heart J 2021
15

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.
Qingchun Zeng, Qing Zhou, Weitao Liu, Yutong Wang, Xingbo Xu, Dingli Xu. Front Cardiovasc Med 2021
2

Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF.
Edimar Alcides Bocchi, Andréa Biolo, Lidia Zytynski Moura, José Albuquerque Figueiredo Neto, Carlos Eduardo Lucena Montenegro, Denilson Campos de Albuquerque. Arq Bras Cardiol 2021
0


Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility.
Giulia Ferrannini, Gianluigi Savarese, Lars Rydén. Diabetes Res Clin Pract 2021
0

SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?
Steffen Pabel, Nazha Hamdani, Mark Luedde, Samuel Sossalla. Curr Heart Fail Rep 2021
0

Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
Silvio E Inzucchi, David Fitchett, Dubravka Jurišić-Eržen, Vincent Woo, Stefan Hantel, Christina Janista, Stefan Kaspers, Jyothis T George, Bernard Zinman. Diabetes Obes Metab 2020
31



Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential.
Dulce Brito, Paulo Bettencourt, Davide Carvalho, Jorge Ferreira, Ricardo Fontes-Carvalho, Fátima Franco, Brenda Moura, José Carlos Silva-Cardoso, Rachel Tavares de Melo, Cândida Fonseca. Cardiovasc Drugs Ther 2020
4

Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes.
Oliver Schnell, Paul Valensi, Eberhard Standl, Antonio Ceriello. Endocrinol Diabetes Metab 2020
2